Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 11, 2012 (15 years ago)

Propofol Injectable Emulsion

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Particulate Matter: A single visible particulate was observed in a retention sample bottles identified as stainless steel

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Propofol Injectable Emulsion, 1%, (10mg/mL), packaged in a) 200 mg/20 mL, 5 Units x 20 mL Single patient infusion vials per carton (NDC 0409-4699-30); b) 1 g/100 mL, 10 Units x 100 mL Single patient infusion vials per carton (NDC 0409-4699-24); Rx only, Hospira, Inc., Lake Forest, IL 60045, USA.

Affected NDCs 0409-4699-24 0409-4699-30

Compare with the code on your package — it is the most precise check available.

Drug: Propofol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Propofol
NDC 00409-4699
10 mg/mL Injection, Emulsion
Intravenous
Hospira, Inc. Rx
Recalling firm
Hospira, Inc.
NDC code
0409-4699-30
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1382-2012 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Propofol recalls

See all
Class II · Moderate risk

Diprivan (Propofol)

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 63323-269-29 D-1116-2022
Class II · Moderate risk

Diprivan (Propofol)

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 63323-269-10 D-1115-2022

Other recalls by Hospira, Inc.

All 2012 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016